YOU ARE HERE:
Kaletra receives EU marketing approval; developing countries registration 'moving forward'
The Meltrex tablet formulation of Kaletra (lopinavir/ritonavir) has now received full marketing approval from the European Medicines Agency (EMEA), according to a statement from the drug's manufacturer, Abbott, who says this now allows them to register the new formulation in countries eligible for its access programme, which offers the drug at a steeply discounted price in more than 60 least developed countries.
The main benefit of the new Kaletra tablet is that it does not need to be refrigerated. Previous studies have found that Kaletra capsules are likely to deteriorate rapidly in resource-limited settings with hot climates and need to be stored and dispensed with care.
Abbott's press release says that European Union (EU) "approval will complement Abbott's efforts to expedite registration filings for the tablet formulation in countries around the world, including in developing countries. To date, Abbott has filed for registration of the new tablet formulation in countries in Africa, Asia and Latin America. Many developing countries require documentation of European approval as part of the filing process for the new tablet formulation. Abbott will be obtaining the necessary documentation and moving forward with the filing process in these countries."
Abbott has previously been criticised by Médecins Sans Frontières for not expediting registration of the new tablet, which is urgently required for second-line treatment in developing countries. Abbott claimed that they required EU approval first, since the tablet is manufactured in Germany, and many African regulatory authorities require a certificate of pharmaceutical production from the EU. However, MSF disputes this explanation. Abbott has also said that it will offer the new tablet to least developed countries at a deeply discounted annual price of $500.
Other benefits of the new tablet include dosing with or without food and a reduced pill count for those on standard dosing (400mg lopinavir/100mg ritonavir) twice daily.
In the United States the orange gel capsule formulation was withdrawn within a few months of the tablet's approval, in order to avoid confusion between the two formulations. Abbott says that "the vast majority of patients will convert to the tablet formulation", but does not give a specific timeframe for this in Europe. They advise individuals currently on the gel capsule formulation to "finish taking their current supply before starting a new prescription", and that they "should never take Kaletra tablets and capsules together.
Individuals who require a non-standard dose of Kaletra - for example, two or four capsules twice-daily - and who are unable to switch to the new tablets will be able to remain on the capsules, at least for the moment. "Capsules will remain available in special cases where they are needed, including paediatrics," says Abbott.
Abbott told AIDS Treatment Update two months ago that it is committed to helping people who are on non-standard dosing, and are developing a half-dose tablet to replace the foul-tasting liquid Kaletra aimed at children - although this will not be available until at least the end of next year.
In addition, Abbott claims that manufacturing a similar Meltrex version of ritonavir (Norvir), which is used to boost rival drug companies' protease inhibitors, is proving even more complex than developing the Kaletra tablet, and that this will not be available any time soon.
The main benefit of the new Kaletra tablet is that it does not need to be refrigerated. Previous studies have found that Kaletra capsules are likely to deteriorate rapidly in resource-limited settings with hot climates and need to be stored and dispensed with care.
Abbott's press release says that European Union (EU) "approval will complement Abbott's efforts to expedite registration filings for the tablet formulation in countries around the world, including in developing countries. To date, Abbott has filed for registration of the new tablet formulation in countries in Africa, Asia and Latin America. Many developing countries require documentation of European approval as part of the filing process for the new tablet formulation. Abbott will be obtaining the necessary documentation and moving forward with the filing process in these countries."
Abbott has previously been criticised by Médecins Sans Frontières for not expediting registration of the new tablet, which is urgently required for second-line treatment in developing countries. Abbott claimed that they required EU approval first, since the tablet is manufactured in Germany, and many African regulatory authorities require a certificate of pharmaceutical production from the EU. However, MSF disputes this explanation. Abbott has also said that it will offer the new tablet to least developed countries at a deeply discounted annual price of $500.
Other benefits of the new tablet include dosing with or without food and a reduced pill count for those on standard dosing (400mg lopinavir/100mg ritonavir) twice daily.
In the United States the orange gel capsule formulation was withdrawn within a few months of the tablet's approval, in order to avoid confusion between the two formulations. Abbott says that "the vast majority of patients will convert to the tablet formulation", but does not give a specific timeframe for this in Europe. They advise individuals currently on the gel capsule formulation to "finish taking their current supply before starting a new prescription", and that they "should never take Kaletra tablets and capsules together.
Individuals who require a non-standard dose of Kaletra - for example, two or four capsules twice-daily - and who are unable to switch to the new tablets will be able to remain on the capsules, at least for the moment. "Capsules will remain available in special cases where they are needed, including paediatrics," says Abbott.
Abbott told AIDS Treatment Update two months ago that it is committed to helping people who are on non-standard dosing, and are developing a half-dose tablet to replace the foul-tasting liquid Kaletra aimed at children - although this will not be available until at least the end of next year.
In addition, Abbott claims that manufacturing a similar Meltrex version of ritonavir (Norvir), which is used to boost rival drug companies' protease inhibitors, is proving even more complex than developing the Kaletra tablet, and that this will not be available any time soon.
aidsmap resources
Africa news
- People with HIV providing high quality treatment support in community
- Nurse prescribing of ARVs: evidence of success in Rwanda and Lesotho
- Cost-effective ways to reduce loss to follow-up in ART programmes identified
Asia and Pacific news
- Screening tool for HIV in children not being used effectively by health care workers
- Water treatment does not reduce diarrhoea in infants born to Kenyan mothers with HIV
- Pain widespread and rarely relieved in Indian patients with HIV
Changing treatments news
- Multiple treatment failures occur less frequently but remain associated with high mortality rates in North American cohort
- Dual maintenance therapy with atazanavir plus raltegravir sustains viral suppression
- Boosted protease inhibitor regimens with 3TC work despite M184V resistance
Developed world news
- Deportation of migrants with HIV often contravenes human rights treaties
- People with HIV have 21-year reduction in life expectancy in US
- HIV health problems cause few problems in employment, but discrimination still a reality in UK
Eastern Europe and Russia news
- Russia urged to expand prevention for injecting drug users
- World Bank: Financial crisis threatens HIV treatment for 1.7 million
- HIV diagnoses in European MSM have almost doubled since 2000, UK tops the list
Latin America news
- Non-AIDS-related deaths becoming more common in Rio de Janeiro HIV patients
- Taking HIV treatment before conception increases risk of having a premature or low weight baby, Brazilian study shows
- CD4 cell count increases sustained up to five years in developing-world treatment programmes
New drugs news
- New hepatitis C protease inhibitors achieve 80% ‘cure’ rate in patients with genotype 1 infection
- FDA committee recommends approval of maraviroc for first-line treatment in US
- Dual maintenance therapy with atazanavir plus raltegravir sustains viral suppression
Treatment access news
feedback
Give us your views on our work